Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 19.27
NAS:DXCM's Cash to Debt is ranked higher than
64% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NAS:DXCM: 19.27 )
Ranked among companies with meaningful Cash to Debt only.
NAS:DXCM' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 19.27 Max: No Debt
Current: 19.27
Equity to Asset 0.74
NAS:DXCM's Equity to Asset is ranked higher than
72% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. NAS:DXCM: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
NAS:DXCM' s Equity to Asset Range Over the Past 10 Years
Min: -0.63  Med: 0.72 Max: 0.92
Current: 0.74
-0.63
0.92
F-Score: 2
Z-Score: 53.48
M-Score: -3.65
WACC vs ROIC
6.06%
-75.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -16.36
NAS:DXCM's Operating margin (%) is ranked lower than
60% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. NAS:DXCM: -16.36 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:DXCM' s Operating margin (%) Range Over the Past 10 Years
Min: -2272.81  Med: -75.93 Max: -8.29
Current: -16.36
-2272.81
-8.29
Net-margin (%) -16.42
NAS:DXCM's Net-margin (%) is ranked lower than
60% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. NAS:DXCM: -16.42 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:DXCM' s Net-margin (%) Range Over the Past 10 Years
Min: -2147.42  Med: -86.02 Max: -8.64
Current: -16.42
-2147.42
-8.64
ROE (%) -37.82
NAS:DXCM's ROE (%) is ranked lower than
67% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. NAS:DXCM: -37.82 )
Ranked among companies with meaningful ROE (%) only.
NAS:DXCM' s ROE (%) Range Over the Past 10 Years
Min: -259.33  Med: -57.04 Max: -19.97
Current: -37.82
-259.33
-19.97
ROA (%) -28.73
NAS:DXCM's ROA (%) is ranked lower than
64% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. NAS:DXCM: -28.73 )
Ranked among companies with meaningful ROA (%) only.
NAS:DXCM' s ROA (%) Range Over the Past 10 Years
Min: -117.86  Med: -56.41 Max: -14.59
Current: -28.73
-117.86
-14.59
ROC (Joel Greenblatt) (%) -78.20
NAS:DXCM's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. NAS:DXCM: -78.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:DXCM' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -851.74  Med: -337.58 Max: -50.89
Current: -78.2
-851.74
-50.89
Revenue Growth (3Y)(%) 51.30
NAS:DXCM's Revenue Growth (3Y)(%) is ranked higher than
95% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. NAS:DXCM: 51.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:DXCM' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 33.8 Max: 103.1
Current: 51.3
0
103.1
EBITDA Growth (3Y)(%) -6.70
NAS:DXCM's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NAS:DXCM: -6.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:DXCM' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -26.75 Max: 0.7
Current: -6.7
0
0.7
EPS Growth (3Y)(%) -3.00
NAS:DXCM's EPS Growth (3Y)(%) is ranked lower than
54% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NAS:DXCM: -3.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:DXCM' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -40  Med: -19.8 Max: 47.3
Current: -3
-40
47.3
» NAS:DXCM's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

DXCM Guru Trades in Q3 2015

Paul Tudor Jones 9,851 sh (New)
Jim Simons 136,643 sh (+407.97%)
RS Investment Management 732,430 sh (+27.72%)
Ron Baron 1,330,742 sh (-0.51%)
Mario Gabelli 45,400 sh (-10.63%)
» More
Q4 2015

DXCM Guru Trades in Q4 2015

Steven Cohen 224,700 sh (New)
George Soros 5,700 sh (New)
Jim Simons 693,943 sh (+407.85%)
RS Investment Management 903,690 sh (+23.38%)
Paul Tudor Jones Sold Out
Mario Gabelli 44,400 sh (-2.20%)
Ron Baron 1,090,473 sh (-18.06%)
» More
Q1 2016

DXCM Guru Trades in Q1 2016

John Paulson 41,300 sh (New)
Andreas Halvorsen 486,489 sh (New)
Jim Simons 817,943 sh (+17.87%)
Steven Cohen 257,900 sh (+14.78%)
Ron Baron 1,092,441 sh (+0.18%)
George Soros Sold Out
Mario Gabelli 43,400 sh (-2.25%)
RS Investment Management 734,086 sh (-18.77%)
» More
Q2 2016

DXCM Guru Trades in Q2 2016

John Paulson 123,500 sh (+199.03%)
Steven Cohen 261,000 sh (+1.20%)
Andreas Halvorsen Sold Out
Mario Gabelli 41,900 sh (-3.46%)
Ron Baron 901,677 sh (-17.46%)
RS Investment Management 309,651 sh (-57.82%)
Jim Simons 341,806 sh (-58.21%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:ERFSF, NYSE:Q, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, NAS:IDXX, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NYSE:DGX, NAS:CPHD, NYSE:ALR, NAS:VWR, NAS:PRXL, NAS:BRKR, NAS:PRAH, OTCPK:CZMWY, NAS:INCR, OTCPK:SSMXY, NAS:NEOG » details
Traded in other countries:DC4.Germany,
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company's product line includes SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.

Ratios

vs
industry
vs
history
Forward P/E 294.12
DXCM's Forward P/E is ranked lower than
100% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. DXCM: 294.12 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 31.68
DXCM's P/B is ranked lower than
98% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. DXCM: 31.68 )
Ranked among companies with meaningful P/B only.
DXCM' s P/B Range Over the Past 10 Years
Min: 3.88  Med: 16.22 Max: 194.65
Current: 31.68
3.88
194.65
P/S 15.53
DXCM's P/S is ranked lower than
85% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. DXCM: 15.53 )
Ranked among companies with meaningful P/S only.
DXCM' s P/S Range Over the Past 10 Years
Min: 6.16  Med: 15.15 Max: 25250
Current: 15.53
6.16
25250
PFCF 950.61
DXCM's PFCF is ranked lower than
98% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.45 vs. DXCM: 950.61 )
Ranked among companies with meaningful PFCF only.
DXCM' s PFCF Range Over the Past 10 Years
Min: 289.28  Med: 556.96 Max: 958.27
Current: 950.61
289.28
958.27
POCF 154.75
DXCM's POCF is ranked lower than
96% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. DXCM: 154.75 )
Ranked among companies with meaningful POCF only.
DXCM' s POCF Range Over the Past 10 Years
Min: 91.4  Med: 164.18 Max: 1366.67
Current: 154.75
91.4
1366.67
Current Ratio 3.26
DXCM's Current Ratio is ranked higher than
63% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. DXCM: 3.26 )
Ranked among companies with meaningful Current Ratio only.
DXCM' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 4.15 Max: 23.47
Current: 3.26
1.96
23.47
Quick Ratio 2.68
DXCM's Quick Ratio is ranked higher than
61% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DXCM: 2.68 )
Ranked among companies with meaningful Quick Ratio only.
DXCM' s Quick Ratio Range Over the Past 10 Years
Min: 1.82  Med: 3.69 Max: 23.47
Current: 2.68
1.82
23.47
Days Inventory 79.36
DXCM's Days Inventory is ranked higher than
55% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. DXCM: 79.36 )
Ranked among companies with meaningful Days Inventory only.
DXCM' s Days Inventory Range Over the Past 10 Years
Min: 23.53  Med: 51.69 Max: 79.36
Current: 79.36
23.53
79.36
Days Sales Outstanding 55.03
DXCM's Days Sales Outstanding is ranked higher than
57% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. DXCM: 55.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
DXCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.96  Med: 54.81 Max: 71.25
Current: 55.03
16.96
71.25
Days Payable 50.16
DXCM's Days Payable is ranked lower than
57% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. DXCM: 50.16 )
Ranked among companies with meaningful Days Payable only.
DXCM' s Days Payable Range Over the Past 10 Years
Min: 21.26  Med: 27.26 Max: 56.11
Current: 50.16
21.26
56.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.50
DXCM's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. DXCM: -5.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DXCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137.6  Med: -16.25 Max: -4.6
Current: -5.5
-137.6
-4.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 266.17
DXCM's Price/Net Cash is ranked lower than
98% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.94 vs. DXCM: 266.17 )
Ranked among companies with meaningful Price/Net Cash only.
DXCM' s Price/Net Cash Range Over the Past 10 Years
Min: 4.94  Med: 36.6 Max: 268.32
Current: 266.17
4.94
268.32
Price/Net Current Asset Value 50.63
DXCM's Price/Net Current Asset Value is ranked lower than
91% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.50 vs. DXCM: 50.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DXCM' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.88  Med: 21.81 Max: 53.03
Current: 50.63
4.88
53.03
Price/Tangible Book 33.51
DXCM's Price/Tangible Book is ranked lower than
95% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.65 vs. DXCM: 33.51 )
Ranked among companies with meaningful Price/Tangible Book only.
DXCM' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.69  Med: 16.33 Max: 143.95
Current: 33.51
4.69
143.95
Price/Median PS Value 1.02
DXCM's Price/Median PS Value is ranked higher than
52% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. DXCM: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
DXCM' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 1.01 Max: 1013.5
Current: 1.02
0.53
1013.5
Earnings Yield (Greenblatt) (%) -1.01
DXCM's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. DXCM: -1.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DXCM' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.37  Med: 0 Max: 0
Current: -1.01
-1.37
0

More Statistics

Revenue (TTM) (Mil) $489.5
EPS (TTM) $ -0.97
Beta0.59
Short Percentage of Float5.91%
52-Week Range $47.92 - 96.38
Shares Outstanding (Mil)83.88

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 578 800 1,086 1,445
EPS ($) -0.45 0.51 1.52 1.56
EPS w/o NRI ($) -0.45 0.51 1.52 1.56
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:DXCM

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight Jun 28 2016 
Baron Funds Comments on DexCom Inc. Jan 14 2016 
Investing for Lower Risk Long-Term Growth in a Volatile Asset Class - Baron Funds Winter Newsletter Jan 14 2016 
Top Weekly Insider Sells Highlights Sep 15 2015 
Weekly CFO Sells Highlight: Gilead Sciences, DexCom, and Palo Alto Networks Sep 13 2015 
Panic-Proofing the Small Investor Aug 26 2015 
Baron Funds Comments on DexCom Inc. Aug 19 2015 
Weekly CFO Sells Highlight: Cigna Corp, Comcast Corp, and DexCom Inc. Jul 20 2015 
Weekly Insider Sells Highlight: GILD, AXTA, GME, DXCM Jul 14 2015 
Weekly CFO Sells Highlight: Axalta Coating Systems Ltd, Palo Alto Networks Inc, DexCom Inc. Jul 13 2015 

More From Other Websites
DexCom Schedules Third Quarter 2016 Earnings Release and Conference Call for November 1, 2016 at... Sep 27 2016
ETF’s with exposure to DexCom, Inc. : September 22, 2016 Sep 22 2016
BTIG Moves To Neutral On DexCom, But Says Shares Are Not Overvalued Sep 14 2016
Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent... Sep 07 2016
Reimbursement of Dexcom CGM Technology for Patients with Type 1 and Type 2 Insulin-Dependent... Sep 07 2016
ETF’s with exposure to DexCom, Inc. : September 6, 2016 Sep 06 2016
DexCom Announces Upcoming Conference Presentation Sep 01 2016
DexCom Announces Upcoming Conference Presentation Sep 01 2016
ETF’s with exposure to DexCom, Inc. : August 23, 2016 Aug 23 2016
ETF’s with exposure to DexCom, Inc. : August 9, 2016 Aug 09 2016
DEXCOM INC Financials Aug 09 2016
DexCom, Inc. :DXCM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 Aug 08 2016
DexCom Launches New Clinic Portal for the DexCom CLARITY® Diabetes Management Solution Aug 08 2016
DexCom Launches New Clinic Portal for the DexCom CLARITY® Diabetes Management Solution Aug 08 2016
Cramer’s Exec Cut: How Nike plans to win big in Rio Aug 05 2016
Jim Cramer's Top Takeaways: Johnson Controls, DexCom Aug 05 2016
Cramer Remix: This could make Apple roar higher Aug 04 2016
DexCom (DXCM) Q2 Loss Wider than Expected, Stock Down Aug 03 2016
DexCom Announces Upcoming Conference Presentations Aug 03 2016
DexCom Announces Upcoming Conference Presentations Aug 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)